Treatment review and update for myasthenia gravis.
Myasthenia gravis (MG) is the best understood autoimmune disease, with well-characterized humoral and cellular effector mechanisms. It is not surprising, therefore, that immunotherapies play a key role in the management of MG. Significant progress has been made over the last few decades in the treatment of patients with MG, and the number of effective avenues of therapy continue to increase. In this review, we provide an update on management options in MG, highlighting recent literature on both traditional and more novel approaches.